摘要
目的:探讨黄芪对急性白血病病人可溶性细胞间黏附分子-1和可溶性血管细胞黏附分子-1水平的影响。方法:64例初治急性白血病患者随机分为化疗组32例和化疗加黄芪组32例,采用酶联免疫吸附测定方法(EuSA法),对治疗前后的血清可溶性细胞间黏附分子-1和可溶性血管细胞黏附分子-1水平进行检测。结果:①与正常组比较,急性白血病病人治疗前后可溶性细胞间黏附分子-1和可溶性血管细胞黏附分子-1水平升高(P<0 05)。②治疗后,化疗加黄芪组与化疗组血清可溶性细胞间黏附分子-1和可溶性血管细胞黏附分子-1水平均下降(P<0 05),化疗加黄芪组下降尤为明显(P<0 05)。结论黄芪可通过降低白血病血清sICAM-1和sVCAM-1水平的而发挥抗肿瘤作用。
Objective： To investigate the effects of astragalion soluble vascularcel adhesion molecules-1 and soluble intercellular cell adhesion molecul-1 levels in patients with acute leukemia. Methods： 64 patients with acute leukemia randomized into chemotherapy group （n=32） and chemotherapy plus astragali group（n=32 ）. Serum samples were obtained from acute leucemia patients before and after treatment. All serum samples were measured for concentrations of soluble vascularcel adhesion molecules-1 and soluble intercellular cell adhesion molecul-1 with enzyme linked immunosorbent assay（ELISA） method. Results： Serum levels of soluble vascularcel adhesion molecules-1 and soluble intercellular cell adhesion molecule-1 in acute leukemia patients elevated significantly before and after treatment compared with normal controls （P〈0 05 ）. After treatment, serum levels of soluble vascularcel adhesion molecules-1 and soluble intercellular cell adhesion molecule-1 of acute leukemia patients in the chemotherapy group and chemotherapy plus astragali group all decreased （P〈0 05 ）, especially obvious in chemotherapy plus astragali group （P〈0 05 ）. Conclusion： Astragali can play an anti-tumor role by reducing levels of soluble vascularcel adhesion molecules-1 and soluble intercellular cell adhesion molecule-1 in acute leukemia patients.
出处
《现代生物医学进展》
CAS
2007年第3期384-386,共3页
Progress in Modern Biomedicine
基金
湖南省中医药科研基金(编号2006-6301)
